Lipa

(redirected from Lysosomal Acid Lipase)
Also found in: Dictionary, Medical, Acronyms.

Lipa

A subdivision of the Croatian kuna. A lipa is equal in value to 1/100 of a kuna. See also: Cent.
Farlex Financial Dictionary. © 2012 Farlex, Inc. All Rights Reserved
References in periodicals archive ?
A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2.
(1.) Htmes RW, Barlow SE, Bove K, Qutntantlh NM, Sheridan R, Kohh R Lysosomal Acid Lipase Deficiency Unmasked in Two Children with Nonalcoholic Fatty Liver Disease Pediatrics 2016, 138.
Ala, "Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency," The Lancet Gastroenterology and Hepatology, vol.
Sebelipase (Kanuma) is a lysosomal cholesteryl ester and triacylglycerol-specific enzyme that is indicated for the treatment of lysosomal acid lipase deficiency.
Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders including Kanuma[TM] (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL deficiency).
A fluorometric assay for lysosomal acid lipase using DBS has been developed based on a 4MU fatty acid substrate and a covalent inactivator of the lysosomal acid lipase, which enables the activity of this enzyme to be teased out of the total lipase activity from a collection of enzymes in blood (75).
Its lead programme, SBC-102, is a recombinant human lysosomal acid lipase currently under clinical investigation for the treatment of patients with early onset and late onset Lysosomal Acid Lipase (LAL) Deficiency.
(NASDAQ: ALXN) show that 80% of infants (8 out of 10) with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma (sebelipase alfa) survived beyond 1 year of age, the company said.
For instance, Kanuma, which is used for the genetic condition lysosomal acid lipase deficiency, costs as much as GBP492,000 per patient annually in the UK.
The merger, pending shareholder and regulatory nods, will enable Synageva to proceed with the development of its SBC-102 clinical programme, an enzyme replacement therapy for lysosomal acid lipase (LAL) deficiency.
The differential diagnosis of nontraumatic splenomegaly with hypertriglyceridemia includes: hereditary absence of lipoprotein lipase or apoC-11, rare apoE3 mutations, deficiency of lysosomal acid lipase, or hemophagocytic lymphohistiocytosis (1-3).
Full browser ?